Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Chem Commun (Camb) ; 58(80): 11280-11283, 2022 Oct 06.
Article in English | MEDLINE | ID: mdl-36124703

ABSTRACT

A stepwise two-photon, red light excitation of organorhodium(III) phthalocyanine complexes was found to induce the activation of the axial metal-carbon bond to generate alkyl radicals/aldehydes. The cooperative action of the photouncaging reaction and the photochemical generation of reactive oxygen species were indicated to induce the cell deaths.


Subject(s)
Indoles , Light , Aldehydes , Carbon , Indoles/chemistry , Isoindoles , Reactive Oxygen Species/metabolism
2.
Medicine (Baltimore) ; 98(44): e17801, 2019 Nov.
Article in English | MEDLINE | ID: mdl-31689860

ABSTRACT

RATIONALE: Anti-glomerular basement membrane (GBM) disease is a T cell-mediated disease that has a poor prognosis with conventional therapy. We tested rituximab as a primary therapy to reduce anti-GBM antibody produced by B cells. PATIENT CONCERNS: A 53-year old woman with complaints of a fever, headache and abdominal discomfort showed renal failure with elevated anti-GBM antibody, and renal biopsy revealed crescentic necrotizing glomerulonephritis with linear immunoglobulin G (IgG) 1 deposition along GBM. DIAGNOSES: The patient's plasma contained autoantibodies against Goodpasture antigen, which is the NC domain of collagen IVα3, and CD4-positive helper T cells were found surrounding crescent glomeruli with the coexistence CD20-positive B cells. INTERVENTIONS: Rituximab with steroid and plasma exchange. OUTCOMES: The levels of autoantibody for Goodpasture antigen were reduced, and the patient was able to temporarily withdraw from hemodialysis. LESSONS: B cell depletion with rituximab is effective as an initial therapy for anti-GBM disease.


Subject(s)
Anti-Glomerular Basement Membrane Disease/drug therapy , Immunologic Factors/therapeutic use , Plasma Exchange/methods , Rituximab/therapeutic use , Steroids/therapeutic use , Anti-Glomerular Basement Membrane Disease/blood , Anti-Glomerular Basement Membrane Disease/immunology , Autoantibodies/blood , Combined Modality Therapy , Female , Humans , Middle Aged , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...